English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/113249
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Conformationally-locked N -glycosides: Exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease

AuthorsCastilla, Javier; Rísquez-Cuadro, Rocio; Higaki, Katsumi; Nanba, Eiji; Ohno, Kousaku; Diaz, Yolanda; Ortiz-Mellet, Carmen; García-Fernández, José Manuel; Castillón, Sergio
KeywordsGlycomimetic
Glucocerebrosidase
Gaucher disease
Pharmacological chaperone
Glycosidase inhibitor
Lysosomal storage disorders
Issue Date2015
PublisherElsevier
CitationEuropean Journal of Medicinal Chemistry 90: 258- 266 (2015)
Abstract© 2014 Elsevier Masson SAS. Pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose-2-alkylsulfanyl-1,3-oxazoline (Glc-PSO) structure exhibit an unprecedented specificity as inhibitors of mammalian β-glucosidase. Notably, their inhibitory potency against human β-glucocerebrosidase (GCase) was found to be strongly dependent on the nature of aglycone-type moieties attached at the sulfur atom. In the particular case of υ-substituted hexadecyl chains, an amazing influence of the terminal group was observed. A comparative study on a series of Glc-PSO derivatives suggests that hydrogen bond acceptor functionalities, e.g. fluoro or methyloxycarbonyl, significantly stabilize the Glc-PSO:GCase complex. The S-(16-fluorohexadecyl)-PSO glycomimetic turned out to be a more potent GCase competitive inhibitor than ambroxol, a non glycomimetic drug currently in pilot trials as a pharmacological chaperone for Gaucher disease. Moreover, the inhibition constant increased by one order of magnitude when shifting from neutral (pH 7) to acidic (pH 5) media, a favorable characteristic for a chaperone candidate. Indeed, the fluoro-PSO derivative also proved superior to ambroxol in mutant GCase activity enhancement assays in N370S/N370S Gaucher fibroblasts. The results presented here represent a proof of concept of the potential of exploiting long-range non-glycone interactions for the optimization of glycosidase inhibitors with chaperone activity.
URIhttp://hdl.handle.net/10261/113249
DOI10.1016/j.ejmech.2014.11.002
Identifiersdoi: 10.1016/j.ejmech.2014.11.002
issn: 1768-3254
Appears in Collections:(IIQ) Artículos
Files in This Item:
File Description SizeFormat 
N-glycoside chaperones.pdf474,57 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.